Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Pierre Cherubin"'
Autor:
Andreas Schreiner, Roland Vauth, Marjolein Lahaye, Mikhail V. Ivanov, Jacek Turczyński, Pierre Cherubin, Bernardo Carpiniello
Publikováno v:
International Journal of Methods in Psychiatric Research
Objectives To explore clinical and demographic characteristics impacting patient functioning by determining extent of overlap in factors driving change in Personal and Social Performance (PSP) and other clinical outcomes. Methods Post‐hoc analysis
Autor:
Boran Uglesic, Andreas Schreiner, Ludger Hargarter, Robin Emsley, Abdullah Cem Sengul, Paul Bergmans, Angelina Khannanova, Pierre Cherubin, Antonino Petralia
Publikováno v:
Neuropsychiatric Disease and Treatment
Robin Emsley,1 Ludger Hargarter,2 Paul Bergmans,3 Boran UglešiÄ,4 Abdullah Cem Sengül,5 Antonino Petralia,6 Angelina Khannanova,7 Pierre Cherubin,8 Andreas Schreiner2 1Stellenbosch University, Tygerberg Campus, Cape Town, South Africa; 2Janssen
Autor:
Paul Bergmans, Elsa Lara, Sofia Keim, Ludger Hargarter, Asaf Caspi, Pierre Cherubin, Andreas Schreiner, Daniel Schuepbach, Sajid Suleman, Irina Pinchuk
Publikováno v:
Psychopharmacology
Rationale Long-acting injectable antipsychotic therapies may offer benefits over oral antipsychotics in patients with schizophrenia. Objective This study aimed to explore the safety, tolerability, and treatment response of paliperidone palmitate once
Autor:
María Paz García-Portilla, Pierre Cherubin, Pierre-Michel Llorca, Paul Bergmans, Halise Devrimci-Ozguven, Sung-Wan Kim, Vasilios P. Bozikas, Katalin Pungor, I. Usankova, Dean Najarian, Giuseppe Maina
BACKGROUND: Symptomatic remission (SR) is an important outcome for schizophrenia patients [1]. In pivotal trials, paliperidone 3-monthly formulation (PP3M) demonstrated favorable efficacy and tolerability in schizophrenia, including achievement of SR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377b6f88e4d67ed0b8f9238019630068
https://europepmc.org/articles/PMC6455476/
https://europepmc.org/articles/PMC6455476/
Publikováno v:
Therapeutic Advances in Psychopharmacology. 7:59-65
Background: The negative symptoms of schizophrenia are generally harder to recognize, more difficult to treat than positive symptoms, and have a significant impact on patient functioning and overall outcomes. Treatment with aripiprazole may be associ
Autor:
Paul Bergmans, Pierre Cherubin, Sofia Keim, A Conca, Andreas Schreiner, N Bilanakis, Ludger Hargarter, Antoni Serrano-Blanco, István Bitter
Publikováno v:
Expert Opinion on Pharmacotherapy
Objective: To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chro
Autor:
Marjolein Lahaye, Juan Schronen, A. Carlo Altamura, Adam Janik, Alp Üçok, Pierre Cherubin, Nikolaj G. Neznanov, Andreas Schreiner, Manuel Franco, Kaire Aadamsoo, Mathias Zink, Ludger Hargarter, Philip Gorwood
Publikováno v:
Schizophrenia Research. 169(1-3):393-399
Objective Relapse and acute exacerbation are common in schizophrenia and may impact treatment response and outcome. Evidence is conflicting in respect to superiority of long-acting injectable antipsychotic therapies versus oral antipsychotics in rela
Autor:
H. Devrimci-Ozguven, S.W. Kim, V.P. Bozikas, Giuseppe Maina, Paul Bergmans, Katalin Pungor, María Paz García-Portilla, Pierre Cherubin, Pierre-Michel Llorca, I. Usankova
Publikováno v:
French Journal of Psychiatry. 1:S171-S172
Objectifs Dans les essais pivotaux, la formulation trimestrielle de paliperidone (PP3M) a demontre une efficacite et une tolerance favorables dans la schizophrenie, incluant l’obtention d’une remission symptomatique (RS) [1,2,3]. Cependant, les p
Autor:
Ludger Hargarter, Pierre Cherubin, Andreas Schreiner, G. Corrivetti, Pierre-Michel Llorca, Paul Bergmans, Sofia Keim, B. Cosar, A. Petralia
Publikováno v:
Journal of Psychopharmacology (Oxford, England)
PALMFlexS, a prospective multicentre, open-label, 6-month, phase IIIb interventional study, explored tolerability, safety and treatment response in adults ( n = 231) with non-acute but symptomatic schizophrenia switching to flexibly dosed paliperidon
Autor:
Ludger Hargarter, Martin Lambert, Veronica Chomskaya, Marjolein Lahaye, Gali Joldygulov, Pierre Cherubin, Andreas Schreiner, Eva-Maria Tsapakis, Vasilis P. Bozikas, Marnina Swarz, Flavio Vischia
Publikováno v:
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 19(sup3)
Partial or non-adherence in patients with schizophrenia is common and increases the risk of relapse. This study explored safety, tolerability and treatment outcomes in patients hospitalised for an exacerbation of schizophrenia initiated on maintenanc